newest glp 1 drug Novo's Wegovy becomes first GLP-1 approved for MASH New GLP-1 weight-loss drugs are
Description
By engaging in physical activity, individuals can achieve a more significant calorie deficit, which is fundamental in losing and preventing weight gain
References: Charbonnel B, Cariou B (2011): Pharmacological management of type 2 diabetes: the potential of incretin-based therapies
Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and dual agonist clinical guidance Herts and West Essex ICB
In summary, tirzepatide achieved more pronounced HbA1c reductions with a lower incidence of hypoglycemia at week 52 compared to insulin glargine
